Breadcrumb

Categories Navigation

Asset Publisher

null Unidad de Enfermedades Infecciosas y Microbiología del Hospital Universitario de Valme (Sevilla)
Hospital Universitario de Valme (Sevilla)

Description

Our group consists of health care professionals (physicians, pharmacist and nurses) along with basic scientists working on aspects of HIV infection and HCV infection. Our main ongoing research lines are the following:

  • Epidemiology of HCV infection, now particularly dedicated to screening programs, acute HCV infection and reinfection;
  • Natural history of HIV/HCV coinfection and HCV coinfection, now focused on the risk of hepatocellular carcinoma and clinical events after HCV clearance;
  • Treatment of HCV infection, including linkage to care strategies and elimination strategies in high prevalence groups, as HIV-infected patients;
  • Resistance and susceptibility to HCV infection;
  • Steatosis and steatohepatitis in HIV infection, from diagnosis to treatment add prevention.

As a consequence of these research lines, our group has published 164 papers during the past 10 years, reaching an H index of 25, which corresponds to an average of 15 citations per paper and a global impact factor greater than 800. In the past five years, our group obtained public competitive funding for 9 projects, including a EU project funded by 3rd Health Programme Call. The results of our studies are cited in clinical practice guidelines for HIV treatment (DHHS, BHIVA, GeSIDA), for the management of HCV infection (GEHEP, AEEH, GeSIDA, SAEI) and international clinical decision support resources as Up to Date.

In the diagnostic area, the group led by Dr. Pineda has pioneered the use of biomarkers to measure hepatic injury as a non-invasive alternative to liver biopsy. His group has also pioneered the implantation of transient hepatic elastography as a test to diagnose fibrosis, deriving from it also prognostic possibilities beyond fibrosis.

Currently, the group is involved in a European project that seeks to generate a new model of care for HCV infection in Europe.

Related Assets

Members

Juan A. Pineda
Juan Macías
Nicolás Merchante
Luis M. Real

Related Assets

Related Assets

Publications

  • Clinical progression of Hepatitis C Virus-related chronic liver disease in Human Immunodeficiency Virus-infected patients undergoing highly active antiretroviral therapy. 
    Pineda JA, García-García JA, Aguilar-Guisado M, Ríos-Villegas MJ, Ruiz-Morales J Rivero A, del Valle J, Luque R, Rodríguez-Baño J, González-Serrano M, Camacho A, Macías J, Grilo I, Gómez-Mateos JM.  Hepatology 2007; 46: 622-630. IF: 13.246 (primer decil Gastroenterología y Hepatología) Citas: 134 
  • The Use of Transient Elastometry for Assessing Liver Fibrosis in Patients with HIV and Hepatitis C Virus Coinfection. 
    Vergara S, Macías J, Rivero A, Gutiérrez-Valencia A, González-Serrano M, Merino D, Rìos MJ, García-García A, Camacho A, López-Cortés L, Ruíz J, de la Torre J, Viciana P, Pineda JA  Clin Infect Dis 2007; 45:969–974. IF: 8.216 (primer decil Enfermedades Infecciosas) Citas: 131 
  • Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. 
    Macías J, Berenguer J, Japón MA, Girón JA, Rivero A, López-Cortés LF, Moreno A, González-Serrano M, Iribarren JA, Ortega E, Miralles P, Mira JA, Pineda JA.  Hepatology 2009; 50: 1056-1063. IF: 13.246 (primer decil Gastroenterología y Hepatología) Citas: 158 
  • Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. 
    Pineda JA, Caruz A, Rivero A, Neukam K, Salas I, Camacho A, Palomares JC, Mira JA, Martínez A, Roldán C, de la Torre J, Macías J.  Clin Infect Dis 2010; 51: 788-95. IF: 8.216 (primer decil Enfermedades Infecciosas) Citas: 113 
  • Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus-coinfected patients with compensated liver cirrhosis. 
    Merchante N, Rivero-Juárez A, Téllez F, Merino D, Ríos-Villegas MJ, Márquez-Solero M, Omar M, Camacho C, Macías J, Pérez-Pérez M, Rivero A, Gómez-Mateos J, Pineda JA.  Hepatology 2012; 56: 228-238. IF: 13.246 (primer decil Gastroenterología y Hepatología) Citas: 46 
  • Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients. 
    Macías J, Berenguer J, Japón MA, Girón-González JA, Rivero A, López-Cortés LF, Moreno A, Márquez M, Iribarren JA, Ortega E, Miralles P, Merchante N, Pineda JA.  Hepatology 2012; 56: 1261-1270. IF: 13.246 (primer decil Gastroenterología y Hepatología) Citas: 21 
  • Increasing Incidence of Hepatocellular Carcinoma in HIV-Infected Patients in Spain. 
    Merchante N, Merino E, López-Aldeguer J, Jover F, Delgado-Fernández M, Galindo MJ, Ortega E, Rivero A, Mínguez C, Romero-Palacios A, Padilla S, Márquez-Solero M, Amador C, Ríos-Villegas MJ, Téllez F, Portilla J, Pineda JA.  Clin Infect Dis 2013; 56: 143-150. IF: 8.216 (primer decil Enfermedades Infecciosas). Citas: 30 
  • Low risk of liver decompensation among human immunodeficiency virus/hepatitis C virus-coinfected patients with mild fibrosis in the short-term. 
    Macías J, Mancebo M, Márquez M, Merino D, Téllez F, Rivero A, von Wichmann MA, López-Cortés LF, Merchante N, Santos J, Raffo M, Pérez-Pérez M, Camacho Á, Iribarren JA, Pineda JA.  Hepatology. 2014 Dec 24. doi: 10.1002/hep.27674. [Epub ahead of print] IF: 13.246 (primer decil Gastroenterología y Hepatología). Citas: 5 
  • Liver stiffness predicts variceal bleeding in HIV/HCV-coinfected patients with compensated cirrhosis. 
    Merchante N, Rivero-Juárez A, Téllez F, Merino D, Ríos-Villegas MJ, Ojeda-Burgos G, Omar M, Macías J, Rivero A, Pérez-Pérez M, Raffo M, López-Montesinos I, Márquez-Solero M, Gómez-Vidal MA, Pineda JA; Grupo Andaluz para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI).  AIDS. 2017;31:493-500. IF: 5.019 (primer cuartil Enfermedades Infecciosas). Citas:1 
  • Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus-Infected Patients With Nonalcoholic Fatty Liver Disease. 
    Macías J, Mancebo M, Merino D, Téllez F, Montes-Ramírez ML, Pulido F, Rivero-Juárez A, Raffo M, Pérez-Pérez M, Merchante N, Cotarelo M, Pineda JA; Spanish AIDS Research Network-HEP09 Study Group.  Clin Infect Dis. 2017;65:1012-1019. IF: 8.216 (primer decil Enfermedades Infecciosas). Citas:0 

Related Assets

Network